Sažetak
Background: This study aims to uncover the potential correlation between LTC4S -444 A>C polymorphism and susceptibility to asthma.
Methods: Literatures reporting the correlation between LTC4S -444 A>C polymorphism and susceptibility to asthma published before 1st June, 2019 were searched in PubMed, Embase, Cochrane, Wanfang and CNKI. Eligible literatures were enrolled and their data were extracted. OR and its 95%CI were calculated for assessing the correlation between LTC4S -444 A>C polymorphism and susceptibility to asthma. The included data were weighted by an inverse variance and then analyzed by a fixed or random effects model. Heterogeneity test and sensitivity analysis were performed on the enrolled reports. STATA12.1 and TSA (trial sequential analysis) were utilized for analyses.
Results: Fifteen studies involving 3,791 asthma patients and 2,185 healthy controls were enrolled. No significant correlation was found between the LTC4S -444 A>C polymorphism and susceptibility to asthma according to the results of different models ((Dominant model (D): OR=1.10, 95%CI=0.98-1.23; Recessive model (R): 1.07, 0.84-1.36; Homozygous model (Homo): 1.11, 0.87-1.41; Heterozygous model (Hetero): 1.10, 0.98-1.24; Allele model (A): 1.07, 0.98-1.18). Subgroup analyses carried out in Asian and Caucasian population, as well as in population-based and hospital-based controls obtained the same conclusions.
Conclusions: No significant correlation is identified between the LTC4S -444 A>C polymorphism and susceptibility to asthma. Researches with high-quality and large sample size are required for further validation in multi-center hospital.
Ključne reči
Array
Array
Array
Reference
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.